Page last updated: 2024-11-10

poly(sodium vinyl sulfonate)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

lyapolate: sulfonic acid polymers represent a new class of HIV inhibitors [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3270262
CHEMBL ID2106422
SCHEMBL ID28654
MeSH IDM0588895

Synonyms (58)

Synonym
9002-97-5
nsc-8957
lyapolate
25053-27-4
sodium apolate (inn)
peson (tn)
D04825
lyapolate sodium (usan)
3039-83-6
sodium ethenesulfonate
sodium vinylsulfonate
ethenesulfonic acid, sodium salt
sodium ethylenesulfonate
V0043
vinylsulfonic acid sodium salt
NCGC00185758-01
dtxsid0027513 ,
tox21_301466
NCGC00255242-01
dtxcid207513
cas-3039-83-6
tox21_113468
CHEMBL2106422
AKOS015962100
nsc 8957
f7k3l38z7b ,
unii-f7k3l38z7b
sodium ethylenesulphonate
einecs 221-242-5
ec 221-242-5
ethenesulfonic acid, sodium salt (1:1)
FT-0625733
AKOS015912620
tamol vs
hs 1 (salt)
svs 25
SCHEMBL28654
sodium vinyl sulfonate
sodium vinyl sulphonate
sodium ethylene sulfonate
vinyl sulfonic acid sodium salt
BWYYYTVSBPRQCN-UHFFFAOYSA-M
W-106946
mfcd00007520
sodium vinylsulfonate, 25% aq. soln.
sodium vinylsulfonate (25% in water, ca. 2.3mol/l)
FT-0700547
sodiumvinylsulfonate,tech.ca25%aq.soln.
sodium;ethenesulfonate
Q1969766
AMY22517
vinylsulfonicacidsodiumsalt
sodium vinylsulfonate solution
E81955
CS-0157965
mfcd00084471
sodium poly(vinylsulfonate)
sodium vinylsulfonate (25% in water, ca. 2.3mol/l)

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (58)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (8.62)18.7374
1990's8 (13.79)18.2507
2000's18 (31.03)29.6817
2010's23 (39.66)24.3611
2020's4 (6.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.71 (24.57)
Research Supply Index4.13 (2.92)
Research Growth Index4.83 (4.65)
Search Engine Demand Index22.89 (26.88)
Search Engine Supply Index2.33 (0.95)

This Compound (22.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other61 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]